Prospects and challenges for expert evidence at the UPC
However, expert evidence on economic issues is likely to become increasingly important for UPC proceedings in the near term. CRA consultants Andrew Tepperman,...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA has assisted clients in intellectual property (IP) matters concerning products and services in the life sciences sector, including Hatch-Waxman and BPCIA matters. We have also addressed patent, trademark, and copyright infringement, trade secret misappropriation, and IP licensing. Our experts have quantified damages based on lost profit and reasonable royalty methods and provided opinions on irreparable harm. In addition, we have experience addressing other forms of relief, such as rescission and disgorgement.
Our understanding of the unique dynamics of different therapeutic areas informs assessments of commercial success as a secondary indicator of non-obviousness and the claimed nexus between patented technologies and product success.
However, expert evidence on economic issues is likely to become increasingly important for UPC proceedings in the near term. CRA consultants Andrew Tepperman,...
This CRA Insights shows how research by Joshua Gottlieb and Avi Zenilman reflects market conditions for travel nurses during the COVID-19 pandemic and...